Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04792476
Other study ID # ITPCan
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date December 31, 2022

Study information

Verified date March 2021
Source Intervención Temprana en Psicosis de Cantabria (ITPCan)
Contact Jose Antonio Cortés Fernández
Phone 685961535
Email josecortesfdez@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to estimate the effect of a 3-month High Intensity Interval Training on antipsychotic-induced weight gain in patients with a first episode of psychosis, as well as to determine whether these effects are maintained 9 months after the intervention has ended.


Description:

Weight gain associated with antipsychotic medication has been recognized for years as a very common side effect, occurring mainly during the first months after the start of antipsychotic treatment. Patients with schizophrenia have a risk of obesity 1.5-2 times higher than the general population and the chances of developing physical problems such as hypertension, diabetes, metabolic syndrome, and coronary heart disease are also higher. Patients diagnosed with schizophrenia have a life expectancy of up to 25 years lower than the general population, with cardiovascular disease being the main cause of premature death. The first months of treatment constitute a critical period for the implementation of strategies that could prevent or mitigate this side effect of the medication, as well as the adverse consequences derived from weight gain. This project is the response to the need to implement physical exercise interventions to prevent weight gain in patients with a first psychotic episode.To date, there is little evidence from randomized clinical trials that have used physical exercise as the only intervention to prevent weight gain in the first weeks from the start of antipsychotic treatment. Numerous systematic reviews and meta-analyses have evaluated non-pharmacological interventions to reduce weight in people with severe mental illness, including chronic psychotic disorders. However, there is little research on this type of intervention in patients with a first episode of psychosis. Studies are needed that implement physical exercise programs from the initial phases of antipsychotic treatment, and that are capable of defining the parameters used in the design of an effective physical exercise intervention for the prevention of weight gain in first psychotic episodes.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Age =18 years and =40 years. - Treatment with antipsychotic medication =6 weeks. - Diagnosis of First Episode Psychosis, for inclusion in the ITPCan Clinical Program. Exclusion Criteria: - Pregnancy or breastfeeding - Poorly controlled diabetes. - Moderate or severe intellectual disability. - Current High Intensity Interval Training program. - Any systematic disease that contraindicates High Intensity Interval Training.

Study Design


Intervention

Other:
High Intensity Interval Training
Experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Intervención Temprana en Psicosis de Cantabria (ITPCan)

Outcome

Type Measure Description Time frame Safety issue
Primary Change in weight gain induced by antipsychotic treatment in patients with a first episode of psychosis with a 12-week High Intensity Interval Training. 12 weeks
Primary Change in weight gain induced by antipsychotic treatment in patients with a first episode of psychosis at 9 months after finishing the intervention. 9 months post-intervention
Secondary Change in the lipid metabolism: triglycerides levels, total cholesterol levels, HDL cholesterol levels and LDL cholesterol levels. Dyslipidemia is an abnormal amount of lipids (e.g.,triglycerides, cholesterol and/or fat phospholipids) in the blood.
The normal triglyceride level is between 30 and 150 mg/dL. The normal HDL cholesterol level is between 40 and 60 mg/dL.
12 weeks and 9 months post-intervention
Secondary Change in abdominal obesity measured by waist circumference. Abdominal obesity, also known as central obesity, is when excessive abdominal fat around the stomach and abdomen has built up to the extent that it is likely to have a negative impact on health.
Men are considered to be at high risk from abdominal obesity if their waist measurements are 102 cm or higher, while women are considered to be at high risk if their waist measurements are 88 cm or higher.
12 weeks and 9 months post-intervention
Secondary Change in glycemic measured by fasting plasma glucose, glycosylated hemoglobin HbA1c and insulin. Hyperglycemia, or high blood sugar (also spelled hyperglycaemia) is a condition in which an excessive amount of glucose circulates in the blood plasma.
A subject with a consistent range between 100-126 mg/dl is considered hyperglycemic, while above 126 mg/dl is generally held to have diabetes.
12 weeks and 9 months post-intervention
Secondary Change in hypertension measured by blood pressure. Hypertension (HTN or HT), also known as high blood pressure (HBP), is a long term medical condition in which the blood pressure in the arteries is persistently elevated.
Blood pressure is expressed by two measurements, the systolic and diastolic pressures, which are the maximum and minimum pressures, respectively. Normal blood pressure at rest is within the range of 100-130 millimeters mercury (mmHg) systolic and 60-85 mmHg diastolic.
12 weeks and 9 months post-intervention
See also
  Status Clinical Trial Phase
Completed NCT02319746 - COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE N/A
Completed NCT04248517 - Using mHealth to Optimize Pharmacotherapy Regimens N/A
Not yet recruiting NCT05384392 - Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode N/A
Not yet recruiting NCT05967195 - Trial to Increase FEP Attendance Early Phase 1
Recruiting NCT02334904 - Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI N/A
Completed NCT03962348 - Clinical Interviews With Detainees With Early Psychosis N/A
Recruiting NCT04368039 - Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis N/A